Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tiziana Life Sciences Ltd (TLSA : NSDQ)
 
 • Company Description   
Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage. Tiziana Life Sciences PLC is based in London, United Kingdom.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.78 Daily Weekly Monthly
20 Day Moving Average: 82,223 shares
Shares Outstanding: 97.31 (millions)
Market Capitalization: $76.14 (millions)
Beta: 1.21
52 Week High: $2.80
52 Week Low: $0.53
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.62% -10.07%
12 Week 17.12% 26.58%
Year To Date -18.49% -3.45%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3RD FLOOR 11-12 ST. JAMES`S SQUARE
-
LONDON,X0 SW1 4LB
GBR
ph: 44-20-7495-2379
fax: -
info@tizianalifesciences.com http://www.tizianalifesciences.com
 
 • General Corporate Information   
Officers
Kunwar Shailubhai - Chief Executive Officer; Chief Scientific Officer
Gabriele Marco Antonio Cerrone - Chairman
Vaseem A. Palejwala - Director; Clinical operations
Keeren Shah - Finance Director
Jules S. Jacob - Senior Director; CMC & Non-Clinical Development

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G88912103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 97.31
Most Recent Split Date: 7.00 (2.50:1)
Beta: 1.21
Market Capitalization: $76.14 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.14 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.54
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©